PE20180774A1 - Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos - Google Patents

Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos

Info

Publication number
PE20180774A1
PE20180774A1 PE2018000111A PE2018000111A PE20180774A1 PE 20180774 A1 PE20180774 A1 PE 20180774A1 PE 2018000111 A PE2018000111 A PE 2018000111A PE 2018000111 A PE2018000111 A PE 2018000111A PE 20180774 A1 PE20180774 A1 PE 20180774A1
Authority
PE
Peru
Prior art keywords
baff
lymphocyte activation
activation factor
compound targeting
compounds
Prior art date
Application number
PE2018000111A
Other languages
English (en)
Spanish (es)
Inventor
Sanjaya Singh
Qi Pan
Rachel Rebecca Barrett
Leslie S Johnson
Gupta Pankaj Gupta
Sarah Low
Haixia Wu
Original Assignee
Boehringer Ingelheim Int
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Macrogenics Inc filed Critical Boehringer Ingelheim Int
Publication of PE20180774A1 publication Critical patent/PE20180774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
PE2018000111A 2015-07-23 2016-07-21 Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos PE20180774A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US201662355302P 2016-06-27 2016-06-27

Publications (1)

Publication Number Publication Date
PE20180774A1 true PE20180774A1 (es) 2018-05-07

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000111A PE20180774A1 (es) 2015-07-23 2016-07-21 Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos

Country Status (21)

Country Link
US (3) US10280231B2 (cg-RX-API-DMAC7.html)
EP (1) EP3322436A4 (cg-RX-API-DMAC7.html)
JP (1) JP6866345B2 (cg-RX-API-DMAC7.html)
KR (1) KR102644875B1 (cg-RX-API-DMAC7.html)
CN (1) CN108135976B (cg-RX-API-DMAC7.html)
AU (1) AU2016297575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001255A2 (cg-RX-API-DMAC7.html)
CA (1) CA2993329A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000182A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018001264A2 (cg-RX-API-DMAC7.html)
EA (1) EA201890360A1 (cg-RX-API-DMAC7.html)
IL (1) IL256665B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018000959A (cg-RX-API-DMAC7.html)
MY (1) MY191081A (cg-RX-API-DMAC7.html)
PE (1) PE20180774A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021552628A1 (cg-RX-API-DMAC7.html)
SA (1) SA518390788B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201912593VA (cg-RX-API-DMAC7.html)
TW (2) TWI733685B (cg-RX-API-DMAC7.html)
UA (1) UA125433C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017015433A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AP3953A (en) 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
JP6293120B2 (ja) 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ＩＬ−２３ｐ１９抗体
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA201791734A1 (ru) 2015-02-04 2018-01-31 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения воспалительных заболеваний
CN108135976B (zh) * 2015-07-23 2022-10-18 博灵格英格尔海姆国际股份公司 靶向il-23a和b细胞激活因子(baff)的化合物和其用途
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3233261A1 (en) * 2021-09-30 2023-04-06 Langyong MAO Anti-il23 antibody fusion protein and uses thereof
AU2023416371A1 (en) * 2022-12-28 2025-07-17 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
WO2025170982A2 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
DK2245064T3 (da) 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
AR071698A1 (es) * 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
MX348166B (es) * 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
RS61136B1 (sr) * 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
SG187682A1 (en) * 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
AP3953A (en) * 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
WO2012125850A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Fc variants
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN104125852B9 (zh) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 基于Fc‑受体的亲和色谱
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
EP3456741B1 (en) * 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
WO2014100490A1 (en) * 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
WO2015100246A1 (en) * 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) * 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
CN108135976B (zh) * 2015-07-23 2022-10-18 博灵格英格尔海姆国际股份公司 靶向il-23a和b细胞激活因子(baff)的化合物和其用途

Also Published As

Publication number Publication date
BR112018001255A2 (pt) 2018-09-11
TW202144411A (zh) 2021-12-01
CN108135976B (zh) 2022-10-18
JP6866345B2 (ja) 2021-04-28
IL256665A (en) 2018-02-28
NZ738942A (en) 2025-05-02
MY191081A (en) 2022-05-30
US20190241678A1 (en) 2019-08-08
US20170022294A1 (en) 2017-01-26
IL256665B2 (en) 2023-10-01
IL256665B1 (en) 2023-06-01
SA518390788B1 (ar) 2021-12-26
CO2018001264A2 (es) 2018-05-10
US20210107998A1 (en) 2021-04-15
KR20180028522A (ko) 2018-03-16
JP2018527323A (ja) 2018-09-20
AU2016297575B2 (en) 2021-05-27
MX2018000959A (es) 2018-06-06
TWI733685B (zh) 2021-07-21
EA201890360A1 (ru) 2018-06-29
CA2993329A1 (en) 2017-01-26
EP3322436A2 (en) 2018-05-23
CN108135976A (zh) 2018-06-08
NZ778160A (en) 2025-05-02
KR102644875B1 (ko) 2024-03-06
WO2017015433A3 (en) 2017-03-09
UA125433C2 (uk) 2022-03-09
WO2017015433A2 (en) 2017-01-26
TWI861413B (zh) 2024-11-11
PH12018500151A1 (en) 2018-07-30
AU2016297575A1 (en) 2018-02-15
PH12021552628A1 (en) 2022-06-27
SG10201912593VA (en) 2020-02-27
US11884744B2 (en) 2024-01-30
TW201712030A (zh) 2017-04-01
US10844138B2 (en) 2020-11-24
US10280231B2 (en) 2019-05-07
EP3322436A4 (en) 2019-03-27
CL2018000182A1 (es) 2018-08-31

Similar Documents

Publication Publication Date Title
PE20180774A1 (es) Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
EA201891211A1 (ru) Ингибиторы cxcr2
MX2017015046A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
CL2018000194A1 (es) Compuestos de piridina
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
UY35467A (es) Compuestos orgánicos
DK3317415T3 (da) UTR'er, som forøger translationseffektiviteten for RNA-molekyler
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2017007377A (es) Compuestos organicos.
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их